MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes

NCT ID: NCT02545062

Last Updated: 2015-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

T2D and cognitive impairment are two of the most common chronic condition found in persons 60 years and older. Diabetes type 2 increases with age and studies suggest that the diabetes is one of the risk factor for cognitive impairment and dementia.

Although there is much recent research showing that diabetics at every age have more cognitive impairment and dementia than non-diabetics, relatively little attention has been paid to the implications of this complication in the management of T2D in terms of screening, prevention, education and treatment adherence.

There are now guidelines for periodic evaluation of patients with diabetes as early detection of complications of the disease, but so far there are no similar assessment and monitoring of cognitive function.

In this study the investigators examine cognitive function in young diabetic patients (from 20 to 55) using the MoCa test, that allows detection of mild cognitive impairment, and may be carried out during a visit, an annual advisory diabetes clinic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Patients on a routine visit to the diabetes clinic, who meet the inclusion criteria, will be recruited for the test. They will be given an explanation of the study and the questionnaire by the principal investigator.
2. Sign a consent form.
3. Performance and execution of MOCA test:

* Fingerstick blood glucose for pre-cognitive testing performed (to avoid testing any participant with a serum glucose \< 70 mg/dl);
* In the presence of hypoglycemia, the participant should be given a snack and begin the test only after the glucose level rises. Alternatively delay executing the Test
4. Details from the patient's file are registered, such as: duration of the disease, family history, presence of macro and micro vascular complications, lifestyle, years of education, and the results of relevant laboratory accuracy.
5. For each patient a medical file is opened containing the initials and serial number of his research. All results are then encoded and analyzed anonymously

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group of type 1 and 2 diabetics

A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.

The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.

Group Type EXPERIMENTAL

MoCa test

Intervention Type OTHER

The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.

control group

The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.

Group Type EXPERIMENTAL

MoCa test

Intervention Type OTHER

The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MoCa test

The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* type 1 and 2 diabetes meIlitus
* 20 to 55 years old
* up to 15 years of diabetes disease duration
* fluent speech and read hebrew's language only

* psychiatric disease
* dementia
* chronic use of alcohol or illegal drugs
* use of medication that can alter the attention or cognition of the participant
* active cardiovascular disease in the previous six months before the investigation
* oncology disease in the previous six months before the investigation
Minimum Eligible Age

20 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clalit Health Services

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Viviana Ostrovsky

Dr. (MD) (specialist in Internal Medicine and Endocrinology and Diabetes)

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joel JS Singer, MD

Role: STUDY_DIRECTOR

Clalit Medical Service

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Viviana Ostrovsky

Nes Tziona, Israel, Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Viviana VO Ostrovsky, MD

Role: CONTACT

+972504402029

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Viviana VO Ostrovsky, MD

Role: primary

+972503265303

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DM- MOCA- 1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

DHS MIND Metabolomics
NCT03975309 COMPLETED